Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sepracor prices $500M note deal

SEPR raised $500 million through the sale of senior convertible subordinated notes due

Read the full 135 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE